Skip to main content

Kinnate Biopharma, Inc. (KNTE)

NASDAQ: KNTE · Delayed Price · USD
23.69 -0.48 (-1.99%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap1.09B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out43.68M
EPS (ttm)-2.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,526,237
Open24.33
Previous Close24.17
Day's Range23.50 - 25.71
52-Week Range17.58 - 48.75
Betan/a
AnalystsBuy
Price Target51.00 (+115.3%)
Est. Earnings DateNov 15, 2021

About KNTE

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 ...

IndustryBiotechnology
IPO DateDec 3, 2020
Employees52
Stock ExchangeNASDAQ
Ticker SymbolKNTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is 51.00, which is an increase of 115.28% from the latest price.

Price Target
$51.00
(115.28% upside)
Analyst Consensus: Buy

News

Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results

Announced first patient dosed in Phase 1 trial  evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors

1 month ago - GlobeNewsWire

Should You Buy Kinnate Biopharma (KNTE) Ahead of Earnings?

Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

Other symbols:FSTXHALORUBYSPRB
1 month ago - Zacks Investment Research

Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021

SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...

2 months ago - GlobeNewsWire

Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors

Accomplished immunologist and veteran biopharma executive has extensive experience in advancing pre-clinical stage oncology programs into the clinic Accomplished immunologist and veteran biopharma execu...

2 months ago - GlobeNewsWire

Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expa...

Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team

3 months ago - GlobeNewsWire

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 against...

3 months ago - GlobeNewsWire

Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference

SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ki...

3 months ago - GlobeNewsWire

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

SAN FRANCISCO and SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ki...

4 months ago - GlobeNewsWire

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)---- $KNTE #ASCO--Data highlights pre-clinical activity of KIN-2787 in Class II and Class III BRAF-mutant models

4 months ago - Business Wire

Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors

SAN FRANCISCO and SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ...

4 months ago - GlobeNewsWire

Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results

Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers

5 months ago - GlobeNewsWire

Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index

SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ...

5 months ago - GlobeNewsWire

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...

7 months ago - GlobeNewsWire

Why These 4 Health Care Stocks Are Moving Today

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...

Other symbols:AYTUMYOVOSMT
8 months ago - Benzinga

Why SVB Leerink Is Bullish On Kinnate Biopharma

Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in ...

8 months ago - Benzinga

Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Pu...

SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...

9 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: The IPO Market Is Taught A Thing Or Two In An 8 IPO Week

The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and AMMO Inc., ...

Other symbols:POWWSBTXSEERYQ
9 months ago - Seeking Alpha

KNTE Stock: 13 Things to Know About the Kinnate Biopharma IPO

KNTE stock has rocketed higher by as much as 115% following the Kinnate Biopharma IPO. Here's what you should know right now.

9 months ago - InvestorPlace

Kinnate Biopharma stock more than doubles in trading debut

Kinnate Biopharma shares more than doubled in their trading debut Thursday, after the company upsized its initial public offering and priced it above its proposed range. The stock, trading on Nasdaq und...

9 months ago - Market Watch

Kinnate Biopharma Stock Doubles As IPO Begins Trading

Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.

9 months ago - Investors Business Daily

Kinnate Biopharma upsizes IPO and prices above range at $20 a share

Kinnate Biopharma upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the 11.5 mill...

9 months ago - Market Watch

Kinnate Biopharma Announces Pricing of Initial Public Offering

SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...

9 months ago - GlobeNewsWire

Kinnate Biopharma to offer 11.5 million shares in planned IPO, priced at $18 to $19 each

Kinnate Biopharma set terms for its initial public offering on Wednesday with plans to offer 11.5 million shares priced at $18 to $19 each. The company would raise $218.5 million at the top of that range.

9 months ago - Market Watch

IPO Preview: Kinnate Biopharma Commences $100 Million IPO

The firm is developing treatments for various cancers using a kinase inhibitory approach.

9 months ago - TheStreet